
## **Carl Turesson**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4217826/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Annals of the Rheumatic Diseases, 2020, 79, 19-30.	0.5	667
2	Survival in rheumatoid arthritis: A population-based analysis of trends over 40 years. Arthritis and Rheumatism, 2003, 48, 54-58.	6.7	423
3	Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. Journal of Rheumatology, 2005, 32, 1213-8.	1.0	380
4	Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. Journal of Rheumatology, 2002, 29, 62-7.	1.0	204
5	Pulmonary dysfunction, smoking, socioeconomic status and the risk of developing rheumatoid arthritis. Rheumatology, 2011, 50, 2005-2013.	0.9	187
6	Incidence of Extraarticular Rheumatoid Arthritis in Olmsted County, Minnesota, in 1995–2007 Versus 1985–1994: A Population-based Study. Journal of Rheumatology, 2011, 38, 983-989.	1.0	143
7	Early menopause is an independent predictor of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2012, 71, 378-381.	0.5	101
8	Incidence and mortality rates of biopsy-proven giant cell arteritis in southern Sweden. Annals of the Rheumatic Diseases, 2015, 74, 993-997.	0.5	100
9	Cardiovascular co-morbidity in rheumatic diseases. Vascular Health and Risk Management, 2008, Volume 4, 605-614.	1.0	91
10	Extra-articular rheumatoid arthritis. Current Opinion in Rheumatology, 2013, 25, 360-366.	2.0	90
11	The impact of HLA-DRB1 genes on extra-articular disease manifestations in rheumatoid arthritis. Arthritis Research and Therapy, 2005, 7, R1386.	1.6	84
12	Increased CD4+ T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis. Arthritis and Rheumatism, 2005, 52, 73-79.	6.7	83
13	Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis–associated nonspecific interstitial pneumonia and usual interstitial pneumonia. Arthritis and Rheumatism, 2006, 54, 635-641.	6.7	82
14	Incidence and prevalence of giant cell arteritis and polymyalgia rheumatica: A systematic literature review. Seminars in Arthritis and Rheumatism, 2020, 50, 1040-1048.	1.6	81
15	Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. Annals of the Rheumatic Diseases, 2021, 80, 1086-1093.	0.5	79
16	The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study. Arthritis Research and Therapy, 2015, 17, 118.	1.6	77
17	Genetics of Rheumatoid Arthritis. Mayo Clinic Proceedings, 2006, 81, 94-101.	1.4	75
18	Vasculitis in rheumatoid arthritis. Current Opinion in Rheumatology, 2009, 21, 35-40.	2.0	72

#	Article	IF	CITATIONS
19	Decrease in the incidence of total hip arthroplasties in patients with rheumatoid arthritis - results from a well defined population in south Sweden. Arthritis Research and Therapy, 2011, 13, R67.	1.6	72
20	Association of HLA–C3 and smoking with vasculitis in patients with rheumatoid arthritis. Arthritis and Rheumatism, 2006, 54, 2776-2783.	6.7	71
21	CD56-expressing T cells that have features of senescence are expanded in rheumatoid arthritis. Arthritis and Rheumatism, 2007, 56, 43-57.	6.7	70
22	Cardiovascular risk factors, fitness and physical activity in rheumatic diseases. Current Opinion in Rheumatology, 2007, 19, 190-196.	2.0	65
23	Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians. Arthritis and Rheumatism, 2001, 44, 1170-1176.	6.7	59
24	Management of extra-articular disease manifestations in rheumatoid arthritis. Current Opinion in Rheumatology, 2004, 16, 206-211.	2.0	59
25	High disease activity disability burden and smoking predict severe extra-articular manifestations in early rheumatoid arthritis. Rheumatology, 2009, 48, 416-420.	0.9	59
26	Visual Complications in Patients with Biopsy-proven Giant Cell Arteritis: A Population-based Study. Journal of Rheumatology, 2016, 43, 1559-1565.	1.0	59
27	Endothelial Expression of MHC Class II Molecules in Autoimmune Disease. Current Pharmaceutical Design, 2004, 10, 129-143.	0.9	57
28	Association between testosterone levels and risk of future rheumatoid arthritis in men: a population-based case–control study. Annals of the Rheumatic Diseases, 2014, 73, 573-579.	0.5	57
29	Tumor Necrosis Factor Inhibitors and Cancer Recurrence in Swedish Patients With Rheumatoid Arthritis. Annals of Internal Medicine, 2018, 169, 291-299.	2.0	53
30	Smoking, body mass index, disease activity, and the risk of rapid radiographic progression in patients with early rheumatoid arthritis. Arthritis Research and Therapy, 2018, 20, 82.	1.6	44
31	Cardiovascular morbidity and mortality remain similar in two cohorts of patients with long-standing rheumatoid arthritis seen in 1978 and 1995 in Malmo, Sweden. Rheumatology, 2009, 48, 1600-1605.	0.9	43
32	Rate of Comorbidities in Giant Cell Arteritis: A Population-based Study. Journal of Rheumatology, 2017, 44, 84-90.	1.0	43
33	Autoantibodies in Rheumatoid Arthritis – Laboratory and Clinical Perspectives. Frontiers in Immunology, 2021, 12, 685312.	2.2	43
34	No decrease over time in the incidence of vasculitis or other extraarticular manifestations in rheumatoid arthritis: Results from a community-based study. Arthritis and Rheumatism, 2004, 50, 3729-3731.	6.7	42
35	The impact of obesity on the development and progression of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, 1911-1913.	0.5	42
36	The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. Rheumatology, 2021, 60, 820-828.	0.9	41

#	Article	IF	CITATIONS
37	Nitrosative modifications of the Ca <sup>2+</sup> release complex and actin underlie arthritis-induced muscle weakness. Annals of the Rheumatic Diseases, 2015, 74, 1907-1914.	0.5	40
38	The effect of clinical features and glucocorticoids on biopsy findings in giant cell arteritis. BMC Musculoskeletal Disorders, 2016, 17, 363.	0.8	37
39	Body mass index and the risk of giant cell arteritis-results from a prospective study. Rheumatology, 2015, 54, 433-440.	0.9	33
40	A high body mass index is associated with reduced risk of rheumatoid arthritis in men, but not in women. Rheumatology, 2016, 55, 307-314.	0.9	33
41	Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA). Clinical Rheumatology, 2017, 36, 773-779.	1.0	33
42	Genetics of rheumatoid arthritis: Is there a pattern predicting extraarticular manifestations?. Arthritis and Rheumatism, 2004, 51, 853-863.	6.7	32
43	Increased cartilage turnover and circulating autoantibodies in different subsets before the clinical onset of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 520-522.	0.5	30
44	Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis. Rheumatology, 2020, 59, 3229-3236.	0.9	30
45	Comorbidity in rheumatoid arthritis. Swiss Medical Weekly, 2016, 146, w14290.	0.8	29
46	Clustering of extraarticular manifestations in patients with rheumatoid arthritis. Journal of Rheumatology, 2008, 35, 179-80.	1.0	27
47	An update on polymyalgia rheumatica. Journal of Internal Medicine, 2022, 292, 717-732.	2.7	27
48	Cigarette smoking and the risk of primary Sjögren's syndrome: a nested case control study. Arthritis Research and Therapy, 2017, 19, 50.	1.6	26
49	Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset. Annals of the Rheumatic Diseases, 2022, 81, 1085-1095.	0.5	26
50	High serum cholesterol predicts rheumatoid arthritis in women, but not in men: a prospective study. Arthritis Research and Therapy, 2015, 17, 284.	1.6	23
51	Severe Extraarticular Manifestations in a Community-based Cohort of Patients with Rheumatoid Arthritis: Risk Factors and Incidence in Relation to Treatment with Tumor Necrosis Factor Inhibitors. Journal of Rheumatology, 2017, 44, 981-987.	1.0	23
52	Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique?. RMD Open, 2019, 5, e000994.	1.8	22
53	Course of Grip Force Impairment in Patients With Early Rheumatoid Arthritis Over the First Five Years After Diagnosis. Arthritis Care and Research, 2018, 70, 491-498.	1.5	21
54	Changes and sex differences in patient reported outcomes in rheumatoid factor positive RA–results from a community based study. BMC Musculoskeletal Disorders, 2014, 15, 44.	0.8	20

#	Article	IF	CITATIONS
55	Antibodies to modified citrullinated vimentin are associated with severe extra-articular manifestations in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 2047-2048.	0.5	19
56	Effects of Treatment with Adalimumab on Blood Lipid Levels and Atherosclerosis in Patients with Rheumatoid Arthritis. Current Therapeutic Research, 2018, 89, 1-6.	0.5	19
57	Predictors of unacceptable pain with and without low inflammation over 5 years in early rheumatoid arthritis—an inception cohort study. Arthritis Research and Therapy, 2021, 23, 169.	1.6	18
58	Association Between Bone Mineral Density and Autoantibodies in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2021, 73, 921-930.	2.9	17
59	Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data. Rheumatology, 2022, 61, 3952-3962.	0.9	17
60	Infections Are Associated With Increased Risk of Giant Cell Arteritis: A Population-based Case-control Study from Southern Sweden. Journal of Rheumatology, 2021, 48, 251-257.	1.0	16
61	Epidemiology of biopsy-confirmed giant cell arteritis in southern Sweden—an update on incidence and first prevalence estimate. Rheumatology, 2021, 61, 146-153.	0.9	16
62	Smoking, disease characteristics and serum cytokine levels in patients with primary Sjögren's syndrome. Rheumatology International, 2018, 38, 1503-1510.	1.5	15
63	Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision. RMD Open, 2021, 7, e001987.	1.8	13
64	EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries. Annals of the Rheumatic Diseases, 2020, 79, 1423-1431.	0.5	11
65	Malignancies in Giant Cell Arteritis: A Population-based Cohort Study. Journal of Rheumatology, 2020, 47, 400-406.	1.0	10
66	Predictors of radiographic erosion and joint space narrowing progression in patients with early rheumatoid arthritis: a cohort study. Arthritis Research and Therapy, 2021, 23, 27.	1.6	10
67	The prevalence of moderate to severe radiographic sacroiliitis and the correlation with health status in elderly Swedish men – The MrOS study. BMC Musculoskeletal Disorders, 2013, 14, 352.	0.8	9
68	Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries. Annals of the Rheumatic Diseases, 2022, 81, 789-797.	0.5	9
69	Changes in bone mineral density over 10 years in patients with early rheumatoid arthritis. RMD Open, 2020, 6, e001142.	1.8	8
70	Associations of cigarette smoking with disease phenotype and type I interferon expression in primary Sjögren's syndrome. Rheumatology International, 2019, 39, 1575-1584.	1.5	7
71	Validity of polymyalgia rheumatica diagnoses and classification criteria in primary health care. Rheumatology Advances in Practice, 2019, 3, rkz033.	0.3	6
72	Evaluation of revised classification criteria for giant cell arteritis and its clinical phenotypes. Rheumatology, 2021, , .	0.9	6

#	Article	IF	CITATIONS
73	Proteomic Data Analysis for Differential Profiling of the Autoimmune Diseases SLE, RA, SS, and ANCA-Associated Vasculitis. Journal of Proteome Research, 2021, 20, 1252-1260.	1.8	5
74	Effects of adalimumab treatment on endothelial cell activation markers in the skeletal muscle of patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2014, 32, 883-90.	0.4	5
75	The relation between upper extremity joint involvement and grip force in early rheumatoid arthritis: a retrospective study. Rheumatology International, 2019, 39, 2031-2041.	1.5	4
76	Parity influences the severity of ACPA-negative early rheumatoid arthritis: a cohort study based on the Swedish EIRA material. Arthritis Research and Therapy, 2015, 17, 358.	1.6	3
77	The Relation Between Disease Activity, Patientâ€Reported Outcomes, and Grip Force Over Time in Early Rheumatoid Arthritis. ACR Open Rheumatology, 2019, 1, 507-515.	0.9	3
78	Lifestyle Factors and Disease Activity over Time in Early Axial Spondyloarthritis - The SPondyloArthritis Caught Early (SPACE) Cohort. Journal of Rheumatology, 2021, , jrheum.210046.	1.0	3
79	Trajectory of Healthcare Resource Utilization in Giant Cell Arteritis: A Population-based Study. Journal of Rheumatology, 2021, 48, 1307-1313.	1.0	1
80	Comment on: Epidemiology of biopsy-confirmed giant cell arteritis in southern Sweden—an update on incidence and first prevalence estimate: reply. Rheumatology, 2021, 60, e423-e424.	0.9	1
81	Male Sex Predicts a Favorable Outcome in Early ACPA-negative Rheumatoid Arthritis: Data From An Observational Study Journal of Rheumatology, 2022, , jrheum.211199.	1.0	1
82	164. INCIDENCE AND SEASONAL VARIATION OF BIOPSY-PROVEN GIANT CELL ARTERITIS – REVISITED A 20 YE POPULATION-BASED STUDY FROM SWEDEN. Rheumatology, 2019, 58, .	EARS 0.9	0
83	165. INFECTIONS ARE ASSOCIATED WITH INCREASED RISK OF GIANT CELL ARTERITIS - A POPULATION-BASED CASE-CONTROL STUDY FROM SOUTHERN SWEDEN. Rheumatology, 2019, 58, .	0.9	0
84	Comment on: Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis: reply. Rheumatology, 2021, 60, e262-e263.	0.9	0